Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin

John A. Howe,1 Jianmin Long,1 Stuart Black,1 Robert Chase,1 Patricia McMonagle,1 Stephanie Curry,1 Seth Thompson,1 Mark J. DiNubile,2 and Anita Y. M. Howe1

1Merck Research Laboratories, Kenilworth, New Jersey; and 2Office of the Chief Medical Officer, Merck, North Wales, Pennsylvania

Background. We analyzed the impact of pretreatment variants conferring boceprevir-resistance on sustained virologic response (SVR) rates achieved with boceprevir plus peginterferon-α/ribavirin (P/R) for hepatitis C virus (HCV)-genotype-1 infection.

Methods. NS3-protease-polymorphisms emerging coincident with virologic failure on boceprevir/P/R regimens were identified as resistance-associated variants (RAVs). Baseline samples pooled from 6 phase II or phase III clinical trials were analyzed for RAVs by population sequencing. Interferon (IFN)-responsiveness was predefined as >1 log reduction in HCV-RNA level during the initial 4-week lead-in treatment with P/R before boceprevir was added. The effective boceprevir-concentration inhibiting RAV growth by 50% (EC50) was determined using a replicon assay relative to the wild-type referent.

Results. Sequencing was performed in 2241 of 2353 patients (95.2%) treated with boceprevir. At baseline, RAVs were detected in 178 patients (7.9%), including 153 of 1498 genotype-1a infections (10.2%) and 25 of 742 genotype-1b infections (3.4%) (relative risk, 3.03; 95% confidence interval [CI], [2.01, 4.58]). For IFN-responders, SVR24 (SVR assessed 24 weeks after discontinuation of all study medications) rates were 78% and 76% with or without RAVs detected at baseline, respectively. For the 510 poor IFN-responders, SVR24 rates were 8 of 36 subjects (22.2% [11.7%, 38.1%]) when baseline RAVs were detected vs 174 of 474 subjects (36.7% [32.5%, 41.1%]) when baseline RAVs were not detected (relative likelihood of SVR24 [95% CI], 0.61 [0.32, 1.05]). Sustained virologic response was achieved in 7 of 8 (87.5%) IFN-nonresponders with baseline variants exhibiting ≤2-fold increased EC50 for boceprevir in a replicon assay, whereas only 1 of 15 (7%) IFN-nonresponders with baseline RAVs associated with ≥3-fold increased EC50 achieved SVR.

Conclusions. Baseline protease-variants appear to negatively impact SVR rates for boceprevir/P/R regimens only when associated with decreased boceprevir susceptibility in vitro after a poor IFN-response during the lead-in period.

Keywords. boceprevir; hepatitis C-genotype 1; RAVs; resistance-associated variants.

Drug resistance represents a new challenge to the fast-evolving therapy of chronic hepatitis C virus (HCV) [1–4]. Virologic failure during treatment with directly acting antiviral agents is often accompanied by the emergence of resistance-associated variants (RAVs) [5, 6]. The error-prone HCV RNA-polymerase generates quasi-species of genetically related viruses harboring minor genomic differences [7]. Polymorphic variants associated with decreased susceptibility to some drugs are likely already circulating at low levels in many patients, even before exposure to directly acting antiviral agents [8–11]. Resistance-associated variants may then become the dominant species under selective drug pressure when viral replication is inadequately suppressed [12, 13].
Table 1. Baseline Characteristics and Study Outcomes by Presence or Absence of Baseline RAVs

|                                | Baseline RAVs | No Baseline RAVs | Not Sequenced |
|--------------------------------|---------------|------------------|---------------|
| **N**                          | 178           | 2063             | 111           |
| **Median age, years (range)**  |               |                  |               |
| Gender, n (%)                  |               |                  |               |
| Female                         | 81 (45.5)     | 923 (44.7)       | 49 (44.1)     |
| Male                           | 97 (54.5)     | 1140 (55.3)      | 62 (55.9)     |
| **Self-identified Race, n (%)**|               |                  |               |
| White                          | 158 (88.8)    | 1662 (80.6)      | 96 (86.5)     |
| Black                          | 14 (7.9)      | 337 (16.3)       | 8 (7.2)       |
| Asian                          | 3 (1.7)       | 30 (1.5)         | 6 (5.4)       |
| Other or mixed                 | 3 (1.7)       | 34 (1.6)         | 1 (0.9)       |
| **Region, n (%)**              |               |                  |               |
| Europe                         | 23 (12.9)     | 421 (20.4)       | 27 (24.3)     |
| North America                  | 153 (86.0)    | 1617 (78.4)      | 84 (75.7)     |
| South America                  | 2 (1.1)       | 25 (1.2)         | 0 (0.0)       |
| **HCV subtype, n (%)**         |               |                  |               |
| 1a                             | 153 (86.0)    | 1345 (65.2)      | 73 (65.8)     |
| 1b                             | 25 (14.0)     | 717 (34.8)       | 14 (12.6)     |
| Other                          | 0 (0.0)       | 1 (0.0)          | 24 (21.6)     |
| **HCV-RNA level at entry, n (%)** |           |                  |               |
| ≤400000 IU/mL                  | 20 (11.2)     | 153 (7.4)        | 17 (15.3)     |
| >400000 to ≤800000 IU/mL       | 16 (9.0)      | 142 (6.9)        | 14 (12.6)     |
| >800000 IU/mL                  | 142 (79.8)    | 1768 (85.7)      | 80 (72.1)     |
| **METAIR score, n (%)**        |               |                  |               |
| F0, F1 or F2 (or unknown)      | 155 (87.1)    | 1831 (88.8)      | 102 (88.8)    |
| F3 or F4                       | 23 (8.7)      | 232 (11.2)       | 9 (8.1)       |
| **IL28B genotype, n (%)**      |               |                  |               |
| CC                             | 48 (27.0)     | 361 (17.5)       | 20 (18.0)     |
| CT                             | 52 (29.2)     | 672 (32.6)       | 28 (25.2)     |
| TT                             | 13 (7.3)      | 232 (11.2)       | 8 (7.2)       |
| Unknown                        | 65 (36.5)     | 798 (38.7)       | 55 (49.5)     |
| **Prior treatment history**, n (%) |         |                  |               |
| Naive                          | 159 (89.3)    | 1652 (80.1)      | 95 (85.6)     |
| Incomplete response to P/R     | 11 (6.2)      | 322 (16.1)       | 12 (10.8)     |
| Relapse after P/R              | 8 (4.5)       | 79 (3.8)         | 4 (3.6)       |
| **Study endpoint**             |               |                  |               |
| SVR24                          | 115 (64.6)    | 1326 (64.3)      | 84 (75.7)     |
| All-cause failure (non-SVR24)  | 63 (35.4)     | 737 (35.7)       | 27 (24.3)     |
| Virologic failureb             | 39 (21.9)     | 501 (24.3)       | 16 (14.4)     |
| Nonvirologic failurec          | 24 (12.4)     | 236 (11.4)       | 11 (9.9)      |

Abbreviations: HCV, hepatitis C virus; P/R, peginterferon alfa plus ribavirin; RAV, resistance-associated variant; SVR24, sustained virologic response assessed 24 weeks after discontinuation of all study medications.

a No patient had received a directly acting antiviral agent of any class before enrollment.

b Virologic failure encompasses incomplete response (including discontinuation for futility and lack of efficacy), breakthrough, and relapse.

c Nonvirologic failure includes all non-SVR24 not due to virologic failure.

Boceprevir is a NS3/4A-protease inhibitor approved for treatment of HCV genotype-1 infection in combination with peginterferon-α/ribavirin (P/R). Boceprevir RAVs were (1) initially discovered in the NS3-protease gene after in vitro selection using HCV-replicon cell lines and (2) presumptively confirmed by sequencing the protease gene from viruses emerging in HCV-infected patients coincident with virologic failure on triple therapy with boceprevir plus P/R [4, 5]. These variants were subsequently shown to confer varying degrees of decreased susceptibility to boceprevir when introduced as amino acid substitutions into the recombinant NS3-protease enzyme or wild-type replicons. The common mutants have been mapped to their positions in the 3-dimensional structure of the NS3-protease active site and correlated with their effects on the enzymatic properties of the NS3/4A-protease and the magnitude of resistance conferred in replicon assays. Although RAVs have been well characterized in vitro, their full therapeutic ramifications are still inadequately understood [1, 3, 13–15].

The objective of the current pooled analysis of the clinical trial database was to assess the impact of preexisting variants on treatment outcomes in subjects treated with boceprevir plus P/R. The primary question was if or when detection of RAVs at baseline predict a high likelihood of treatment failure. In particular, we sought to determine whether baseline RAVs at levels detectable by population sequencing (~20% of circulating quasi-species) were associated with treatment failure and whether interferon-responsiveness was a critical cofactor in any relationship between baseline RAVs and SVR. Although the current analysis focused on boceprevir, these data can help inform how baseline variants might impact the efficacy of newer antiviral regimens, including or exclusively consisting of directly acting agents against HCV.

**METHODS**

**Study Design**

Data were gathered from 6 clinical trials (including 1 phase II study [P03523] and 5 phase III studies [P05101, P05216, P05411, P05685, and P06086]) conducted in treatment-naive and treatment-experienced patients with HCV-genotype 1 infection, comparing the then standard P/R therapy to treatment regimens that added boceprevir after an initial 4-week lead-in period with P/R alone [16–21]. Interferon responsiveness was defined per protocol as >1 log reduction in HCV-RNA level during the initial 4-week treatment with P/R before boceprevir was added. Patients exposed to a directly acting antiviral agent were ineligible. Futility rules were prespecified per the protocols; patients in whom study therapy was stopped for futility were considered virologic failures. Circulating viral quasi-species in plasma specimens obtained at baseline and at the time of virologic failure were to undergo population sequencing with a
detection limit for variants of ~20% prevalence [22]. IL28B genotype (rs12979860) was determined using the Illumina BeadChip Technology (San Diego, CA) in 4 studies. Only patients treated with ≥1 dose of boceprevir were eligible for the current analyses.

**Viral and Resistance Assays**

Plasma HCV-RNA levels were measured by the TaqMan 2.0 assay (Roche Diagnostics, Branchburg, NJ) with lower limits of quantification of 25 IU/mL and lower limits of detection of 9.3 IU/mL. To assess genotypic variation at baseline or at virologic failure, the NS3/4A gene was amplified from samples with RNA levels ≥1000 IU/mL using reverse transcription-polymerase chain reaction, followed by population sequencing of the NS3-protease region (amino acid residues 1–181) [23]. Resultant amino acid sequences were compared with wild-type HCV genotype 1a (H77) or 1b (Con1) reference sequences. Amino acid substitutions at 11 loci (V36A/M, T54A/C/G/S, V55A/I, V107I, R155C/K/T, A156S/T/V, V158, D168N, I170A/F/T/V, V170A/F/T, and M175L) alone or in combination were considered to represent RAVs irrespective of genotype-1 subtype because these variants commonly emerged coincident with virologic failure in patients treated with boceprevir/P/R in the pivotal trials.

In phenotypic analyses to measure the antiviral potency of boceprevir against RAVs, genotype-1a (H77) and genotype-1b (Con1) replicon and enzyme constructs were engineered to incorporate NS3-mutations. Stable subgenomic replicons expressing NS3 mutants were constructed in Huh-7 cells. Fold shift in boceprevir susceptibility for each variant replicon was expressed relative to the effective concentration inhibiting viral growth by 50% (EC50) for the subtype-specific wild-type replicon. Boceprevir inhibitory activity against recombinant NS3-enzymes was tested with a chromogenic assay. Inhibition constants from 4 to 8 experiments using a single clone for each variant (Ki*) were averaged, and the fold change in boceprevir susceptibility was expressed relative to the wild-type Ki*.

**RESULTS**

**Subject Accounting and Baseline Characteristics**

Population NS3-sequence data were obtained at baseline from 2241 of 2352 (95.5%) boceprevir recipients, including 1498 of 1571 (95.4%) with genotype-1a infections and 742 of 756 (98.1%) with genotype-1b infections. Baseline characteristics were generally similar in patients with or without baseline RAVs, except that genotype 1a infections were disproportionately represented among the RAVs (Table 1). At baseline, no RAVs were detected by population sequencing in 2063 of 2241 (92%) of patients. Baseline RAVs were identified in 178 of 2241 (7.9%) patients at 8 positions (V36, T54, V55, V107, R155, V158, I170, and M175) of the 11 defined boceprevir resistance-associated NS3-loci. Resistance-associated variants were found in 153 of 1498 (10.2%) patients with genotype-1a virus and in 25 of 742 (3.4%) patients with genotype-1b virus (relative risk of detected RAV at baseline [95% confidence interval] = 3.03 [2.01, 4.58]). In genotype-1a infections, the most common substitutions were I170V, V55A, T54S, and V55I; in genotype-1b infections, the most common substitutions were T54S, V55A, and V107I (Figure 1). No other substitution occurred in ≥10% of cases. The large majority of boceprevir recipients included in our analysis population were treatment-naive at study entry: 1906 of 2352 patients (81.0%) overall, including 159 of 178 patients (89.3%) with RAVs detected at baseline, and 1652 of 2063 patients (80.1.3%) without RAVs detected at baseline. No patient had received a direct-acting antiviral drug before enrollment.

**Phenotypic Susceptibilities of Detected Boceprevir Resistance-Associated Variants**

The effects of RAVs identified at baseline on boceprevir activity were tested in genotype-1a and genotype-1b replicon cell lines, as well as using recombinant NS3-enzymes containing the substituted amino acid, and expressed relative to the wild-type referent (Table 2). Inhibition of enzyme activity was sometimes discordant with the replicon susceptibility for several variants. V55I and V107I in genotype-1a replicons did not result in decreased boceprevir sensitivity, but these substitutions caused 12-fold and 2-fold reductions, respectively, in the enzyme inhibition. V107I in the genotype 1b replicon and I170V in the genotype 1a replicon decreased boceprevir susceptibility by 2-fold but did not reduce enzyme inhibition. Boceprevir activity against all other tested variants was ≥2-fold less than against the wild-type comparator in both assay systems. Genotype-1a or genotype-1b replicons harboring V36M, T54A/S, R155K,
or V55A were ≥3-fold less susceptible to boceprevir than wild-type virus, as were genotype-1b replicons with V158I or M175L.

### Pretreatment Variants and Subsequent Virologic Failure

Among boceprevir recipients, SVR24 (SVR assessed 24 weeks after discontinuation of all study medications) rates were 64.3% (1326 of 2063) when baseline RAVs were not detected and 64.6% (115 of 178) when baseline RAVs were detected. A total of 39 (61.9%) of the 63 patients with baseline RAVs who did not achieve SVR24 experienced virologic failure, including 15 patients who also had RAVs at the time of failure and during follow-up (Table 3). In 13 of the 15 patients, a single RAV containing T54S (n = 1), V55A (n = 5), V55I (n = 1), R155K (n = 1), or I170V (n = 5) was found after virologic failure. Multiple polymorphisms containing V36M, R155K, and I170V (n = 1) or T54S and V55I (n = 1) were detected in the other 2 patients after virologic failure. Among the 5 patients with the single V55A RAV detected at baseline, 3 patients had only V55A detected subsequent to virologic failure, whereas V55A with V36M or V55A with V36L and V158I were identified in 1 patient each after virologic failure. Of the 5 patients with I170V at baseline, none had this variant detected after virologic failure, although V55A (n = 1), A156S (n = 1), A156T (n = 1), or V36M and R155K (n = 2) were found at failure. The patients with either V55I or T54S variants at baseline failed with V36M and V55I or Q41H and T54S, respectively. The only patient with an isolated baseline R155K variant failed with this variant alone, but V36M with R155K was later detected during follow-up.

### Interaction of Pretreatment Variant With IL28B Genotype and Interferon Responsiveness

In our analysis, 78% of boceprevir recipients with the CC genotype achieved SVR24 compared with 64% for patients with either the CT or TT genotype. The SVR24 rates were generally similar for CC and non-CC subjects irrespective of the presence of detected RAVs at baseline (Table 4).

### DISCUSSION

In this pooled analysis of 6 phase II and III studies, baseline RAVs were detected by standard population sequencing in ~8% of patients overall and were 3-fold more prevalent in genotype 1a than genotype 1b infections. Hepatitis C virus genotype 1b has a higher genetic barrier to drug resistance than genotype 1a [9, 13, 24, 25]. The most common baseline RAVs were I170V, V55A, T54S, and V55I in genotype-1a infections and T54S, V55A, and V107I in genotype-1b infections.

Our findings regarding the frequencies and implications of baseline variants with reduced susceptibility to protease inhibitors are generally consistent with earlier reports in the literature [10, 11]. The overall SVR rate of ~65% was not compromised among boceprevir recipients with RAVs detected at baseline. For interferon-responders, SVR24 rates were 78% with RAVs and 76% without RAVs at baseline. In contrast, for the 510 subjects with poor interferon-responses, SVR24 rates were 22% when baseline RAVs were detected vs 37% when baseline RAVs were not detected. Only 1 of 8 interferon-non-responders with baseline RAVs conferring ≥3-fold decrease in boceprevir resistance was cured.

### Table 2. In Vitro Activity of Boceprevir Against Variants Detected at Baseline Relative to Wild-Type Virus Using Replicon and Enzyme Assays

| V36M | T54A | T54S | V55A | V55I | V107I | R155K | V158I | I170V | M175L |
|------|------|------|------|------|-------|-------|-------|-------|-------|
| Replicon |
| GT 1a | 4 | 3 | 3 | 4 | 1 | 1 | 6 | 2 | 2 | na |
| GT 1b | 4 | 6 | 5 | 4 | 2 | 2 | 5 | 5 | na | 3 |
| Enzyme |
| GT 1a | 2 | 7 | 3 | 2 | 12 | 2 | 4 | 2 | 1 | na |
| GT 1b | 2 | 4 | 2 | 4 | 7 | 1 | 4 | nd | na | nd |

Abbreviations: ECso, effective concentration 50%; GT, genotype; Ki*, inhibition constant from 4 to 8 experiments using a single clone for each variant; na, not applicable because the specified substitution is not commonly found in that particular HCV-genotype; nd, not done; RAV, resistance-associated variant.

For interferon-responders during the lead-in treatment period with P/R before the addition of boceprevir, respective SVR24 rates with boceprevir regimens were 76% and 78% for patients with or without RAVs detected at baseline (Table 5). Of the 510 subjects with poor interferon-responses, SVR24 rates were 8 of 36 patients (22.2% [11.7%, 38.1%]) when baseline RAVs were detected vs 174 of 474 patients (36.7% [32.5%, 41.1%]) when baseline RAVs were not detected (relative likelihood of SVR24 [95% confidence interval, 0.61; 0.32, 1.05]). SVR24 was achieved in 7 of 8 (87.5%) interferon-nonresponders with baseline variants exhibiting ≤2-fold increased EC50 for boceprevir in a replicon assay. In contrast, only 1 of 15 (6.7%) interferon-non-responders with a baseline RAV associated with ≥3-fold increased EC50, which contained an isolated V55A substitution, achieved SVR.
| Patient | HCV Genotype | Lead-in P/R Response | Type of Virologic Failure | Sample day | Boceprevir RAVs |
|---------|--------------|----------------------|--------------------------|------------|----------------|
| 1       | 1a           | No                   | Nonresponse              | 0          | V36M, R155K, I170V |
|         |              |                      |                          | 57         | V36M, R155K     |
|         |              |                      |                          | 92         | V36M, R155K     |
|         |              |                      |                          | 113        | V36M, R155K     |
|         |              |                      |                          | 506        | V36M, R155K     |
| 2       | 1a           | No                   | Nonresponse              | 0          | T54S, V55I      |
|         |              |                      |                          | 56         | T54S, V55I      |
|         |              |                      |                          | 502        | T54S, V55I      |
| 3       | 1a           | Yes                  | Relapse                  | 0          | V55A           |
|         |              |                      |                          | 508        | V55A           |
| 4       | 1a           | No                   | Nonresponse              | 0          | V55A           |
|         |              |                      |                          | 57         | V55A           |
|         |              |                      |                          | 169        | V36M, V55A     |
|         |              |                      |                          | 508        | V36M, V55A     |
| 5       | 1a           | Yes                  | Nonresponse              | 0          | V55A           |
|         |              |                      |                          | 203        | V36L, V55A, V158I |
|         |              |                      |                          | 511        | V36L, V55A     |
| 6       | 1a           | No                   | Incomplete response      | 0          | V55A           |
|         |              |                      |                          | 137        | V55A, R155K    |
|         |              |                      |                          | 523        | V55A, R155K    |
| 7       | 1a           | No                   | Nonresponse              | 0          | V55A           |
|         |              |                      |                          | 59         | V55A           |
|         |              |                      |                          | 109        | V55A, R155K/T  |
|         |              |                      |                          | 549        | V55A           |
| 8       | 1a           | Yes                  | Relapse                  | 0          | V55I           |
|         |              |                      |                          | 414        | V36M, V55I     |
|         |              |                      |                          | 512        | V36M, V55I     |
| 9       | 1a           | No                   | Relapse                  | 0          | R155K          |
|         |              |                      |                          | 71         | R155K          |
|         |              |                      |                          | 365        | V36M, R155K    |
|         |              |                      |                          | 505        | V36M, R155K    |
| 10      | 1a           | No                   | Nonresponse              | 0          | I170V          |
|         |              |                      |                          | 225        | A156S          |
|         |              |                      |                          | 526        | A156S          |
| 11      | 1a           | No                   | Nonresponse              | 0          | I170V          |
|         |              |                      |                          | 225        | V36M, R155K    |
| 12      | 1a           | No                   | Relapse                  | 0          | I170V          |
|         |              |                      |                          | 505        | V55A           |
| 13      | 1a           | No                   | Incomplete response      | 0          | I170V          |
|         |              |                      |                          | 71         | V36M, R155K    |
|         |              |                      |                          | 99         | V36M, R155K    |
|         |              |                      |                          | 265        | V36M, R155K    |
| 14      | 1a           | No                   | Incomplete response      | 0          | I170V          |
|         |              |                      |                          | 56         | A156T          |
|         |              |                      |                          | 84         | V36M, R155K, A156S, V158I |
|         |              |                      |                          | 95         | V36M, R155K, A156S, V158I |
| 15      | 1b           | Yes                  | Relapse                  | 0          | T54S           |
|         |              |                      |                          | 445        | O41H, T54S     |

Abbreviations: HCV, hepatitis C virus; P/R, peginterferon alfa plus ribavirin; RAV, resistance-associated variant.

* Day 0 indicates samples obtained at baseline. Lead-in refers to the first 4 weeks of P/R therapy before boceprevir was added.
susceptibility in vitro achieved SVR. In contrast to the empiric demonstration of interferon-responsiveness during the lead-in period, the IL28B genotype (a marker of interferon responsiveness) did not influence SVR results as a function of the presence or absence of baseline RAVs.

Not all baseline and emergent HCV-protease variants will actually confer clinically meaningful drug resistance. Before interpretive guidelines for genotypic resistance testing can be established for a given drug, RAVs must be distinguished from therapeutically inconsequential polymorphisms based on extensive clinical correlation. Phenotypic resistance testing using our replicon and enzyme assays did not always yield concordant results. For the purposes of the current analysis, NS3-protease polymorphisms emerging coincident with virologic failure in patients treated with boceprevir/P/R regimens were considered to represent RAVs. When accompanied by poor responses to P/R, the baseline polymorphisms among these variants conferring relatively high levels of boceprevir resistance in vitro predicted failure to achieve SVR, presumably because boceprevir plus P/R approximates functional monotherapy under these conditions.

Our pooled analysis has several noteworthy limitations. The study was retrospective and encompassed 6 different protocols. By missing minor variants, population-based sequencing as used here likely underestimated the frequency of potentially relevant RAVs [22]. Although the lessons may be generalizable to other treatment paradigms, interferon-based regimens are being phased out [26, 27]. At least in the developed world, boceprevir use is rapidly diminishing in favor of other directly acting antiviral drug combinations that achieve SVR rates exceeding 90% [26–28].

The prognostic utility of baseline resistance testing requires continued scrutiny as the use of different classes of directly acting antiviral agents for chronic HCV infection becomes increasingly widespread. In addition to the infecting HCV-genotype, a recent history of failure on an interferon-sparing regimen may affect the probability of detecting drug-specific or class-wide RAVs at a given point in time. Because combination therapy is universally recommended, baseline variants might not impact outcome unless abundant RAVs, high-level resistance, poor interferon-responsiveness, cross-resistance to other coadministered antiviral agents, and/or erratic compliance with an unforgiving regimen are concurrently present. In our pooled analysis using clinically relevant outcomes, baseline NS3-protease-variants negatively impacted SVR rates in patients treated with boceprevir/P/R regimens most when associated with decreased susceptibility to boceprevir in vitro coupled with a poor interferon response during the lead-in period. As the number of directly acting antiviral agents expands, these data may instruct clinicians about general principles underlying the interpretation of resistance testing in selecting combination regimens to treat individual patients.

**Acknowledgments**

We are indebted to all the patients, healthcare providers, and investigators involved with the parent studies. We also thank Karyn Davis from Merck for technical assistance in the preparation of this manuscript.

**Disclaimer.** The opinions expressed in this report represent the consensus of the authors and do not necessarily reflect the formal position of Merck.

**Financial support.** The parent studies and the current analysis were sponsored and funded by Merck.

**Potential conflicts of interest.** Merck markets boceprevir under the brand name Victrelis. The company sponsored and funded the parent studies and the derivative analysis reported here. As employees of Merck, the authors own stock and/or stock options in the company. All authors had

---

**Table 4. SVR24 Rates in Patients With and Without Baseline RAVs by (A) IL28B Genotype (CC vs CT/TT) at the End of the 4-Week Lead-in Treatment Period With P/R Before Boceprevir Was Added**

| IL28B Genotype        | CC (N = 409) | Non-CC (N = 969) |
|-----------------------|--------------|------------------|
|                       | Patients     | SVR Rate         | Patients     | SVR Rate         |
|                       | (n/m)        |                  | (n/m)        |                  |
| Subjects without baseline RAVs (N = 1265) | 282/361      | 78%              | 571/904      | 63%              |
| Subjects with baseline RAVs (N = 113)    | 36/48        | 75%              | 43/65        | 66%              |

**Table 5. Interferon Response (>1 Log Reduction From Baseline HCV-RNA Level) at the End of the 4-Week Lead-in Treatment Period With P/R Before Boceprevir Was Added**

| Interferon Responsiveness | Interferon Responders (N = 1447) | Interferon Nonresponders (N = 510) |
|---------------------------|----------------------------------|-----------------------------------|
|                           | Patients (n/m)  | SVR Rate | Patients (n/m)  | SVR Rate |
|                           |                  |          |                  |          |
| Subjects without baseline RAVs (N = 1822) | 1009/1327       | 76%      | 174/474         | 37%      |
| Subjects with baseline RAVs (N = 158) | 94/120           | 78%      | 8/36             | 22%      |

Abbreviations: HCV, hepatitis C virus; N, number of patients in the category evaluable for the SVR analysis of RAVs x interferon responsiveness; n/m, number of patients with SVR/number of patients satisfying the characteristics for the specified cell; P/R, peginterferon alfa plus ribavirin; RAV, resistance-associated variant; SVR, sustained virologic response; SVR24, sustained virologic response assessed 24 weeks after discontinuation of all study medications.
full access to any pertinent data upon request. Each coauthor approved an essentially final version of the manuscript. A penultimate version of the paper was reviewed by the sponsor.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Welsch C, Zeuzem S. Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol 2012; 2:651–5.
2. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767–77.
3. Gambarin-Gelwan M, Jacobson IM. Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep 2012; 14:47–54.
4. HCV DrAG Phenotype and Sequence Analysis Working Group. Ann Forum Collab HIV Res. Available at: http://www.idsociety.org/uploadedFiles/IDSA/Hepatitis_C/For_IDSA_Members/ForumforCollaborativeHIV-ClinicallyRelevantHCVDrug.pdf. Accessed 29 January 2014.
5. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444:329–36.
6. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57:221–9.
7. Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4a protease inhibitors. PLoS Pathog 2012; 8:1–15.
8. Ribeiro RM, Li H, Wang S, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012; 8:e1002881.
9. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 2011; 16:1093–102.
10. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984–7.
11. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87:1544–53.
12. Rong L, Dahari H, Ribeiro RM, et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.